If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The workshop was conducted as a part of the NITI–State workshop series
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Mpower an initiative of Aditya Birla Education Trust works in the space of Mental health
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Advancing to IND-enabling studies with multiple drug candidates
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
The centres will be located in Tier I and Tier II cities
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
